NCT03795142 is a EARLY_PHASE1 clinical trial of BGB149 in Healthy Volunteers, sponsored by BerGenBio ASA.

Who is sponsoring NCT03795142?

NCT03795142 is sponsored by BerGenBio ASA.

What drugs are being tested in NCT03795142?

Interventions in NCT03795142: BGB149, Placebo.

What condition does NCT03795142 study?

NCT03795142 studies Healthy Volunteers.

Is NCT03795142 still recruiting?

NCT03795142 is currently completed. Last updated 16 March 2022.

Last reviewed 2022-03-16 · How we verify

NCT03795142

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A First-time-in-human Study of BGB149

Completed EARLY_PHASE1 Last updated 16 March 2022

What this trial tests

EARLY_PHASE1 trial testing BGB149 in Healthy Volunteers in 24 participants. Completed in 31 October 2019.

Timeline

19 December 2018

Primary endpoint
31 October 2019

31 October 2019

Quick facts

Lead sponsor	BerGenBio ASA
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	screening
Enrollment	24
Start date	19 December 2018
Primary completion	31 October 2019
Estimated completion	31 October 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

BGB149 — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

BerGenBio ASA — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is a Phase I, first-in-human. The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of BGB149 after single IV doses in healthy male and female subjects. Multiple dose levels will be explored.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

AXL as a Target in Breast Cancer Therapy.
Colavito SA. · · 2020 · cited 50× · PMID 32148495 · DOI 10.1155/2020/5291952

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other BerGenBio ASA trials

Trials by the same sponsor.

NCT05469178 — A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell · Phase 1, PHASE2 · terminated
NCT06469138 — A Study to Investigate 14C-bemcentinib in Healthy Male Subjects · Phase 1 · completed
NCT04893551 — A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants · Phase 1 · terminated
NCT04890509 — A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients · Phase 2 · completed
NCT03184571 — Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03795142 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BerGenBio ASA
Last refreshed: 16 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03795142.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing